BYSI, PHUN and DTSS among pre-market losers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2024
0mins
Should l Buy ODD?
Source: SeekingAlpha
- Losers: Several companies experienced stock price declines after Q4 earnings releases, including Entravision Communications Corp., Thor Industries, BeyondSpring, ODDITY Tech Ltd., Phunware, Foot Locker, Nordstrom, Grifols, Zhongchao, Datasea, China Jo-Jo Drugstores, Ainos, Vanda Pharmaceuticals, Roma Green Finance Limited, Winnebago Industries, CASI Pharmaceuticals, Renalytix, Adial Pharmaceuticals, ChargePoint Holdings, and Xeris Biopharma Holdings.
- Datasea: Datasea's stock jumped 23% due to a potential $30M sale agreement by its subsidiary.
- BeyondSpring: Seeking Alpha provided a Quant Rating on BeyondSpring, and there was historical earnings data available for the company.
- BeyondSpring: Financial information was available for BeyondSpring.
- Datasea: Financial information was available for Datasea.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ODD
Wall Street analysts forecast ODD stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 14.740
Low
49.00
Averages
66.63
High
80.00
Current: 14.740
Low
49.00
Averages
66.63
High
80.00
About ODD
Oddity Tech Ltd is an Israel-based company engaged in the beauty and wellness sector. The Company is operating a tech platform under its own brand on the Internet, whose purpose is to support a portfolio of brands and services connected to the beauty and wellness market and to develop products customized to the wishes of the Company's clients. The Company is using algorithms and machine learning models to match a corresponding physical product. Advanced biological models and machine learning-based tools are used to find new molecules for beauty and wellness purposes. The Company is active in research and development in areas such as data science, machine learning, and computer vision to enhance its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oddity Tech Faces Securities Litigation Investigation
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Oddity Tech Ltd., reminding investors of the May 11, 2026 deadline to seek lead plaintiff status in a federal securities class action filed against the company.
- Investor Loss Focus: Securities litigation partner James (Josh) Wilson encourages investors who purchased or acquired Oddity securities between February 26, 2025, and February 24, 2026, to contact him directly to discuss their legal rights and possible remedies.
- Contact Information Provided: Investors can reach Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information and to understand their legal options regarding the ongoing investigation.
- Significance of Class Action: This investigation and the forthcoming lawsuit could negatively impact Oddity's stock price and corporate reputation, prompting investors to closely monitor developments to safeguard their interests.
See More
Reminder of Class Action for ODDITY Tech Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased ODDITY Tech Ltd. (NASDAQ: ODD) common stock between February 26, 2025, and February 24, 2026, that they must apply to be lead plaintiff by May 11, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to seek legal recourse without financial burden.
- Lawsuit Background: The lawsuit alleges that defendants misled investors by providing overly optimistic information about ODDITY Tech's 2027 financial targets while concealing the true state of its salesforce, resulting in investor losses once the actual details became public.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, including the largest securities class action against a Chinese company, demonstrating its extensive experience and success in handling such cases.
See More
Oddity Tech Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Berger Montague PC has announced a class action lawsuit against Oddity Tech on behalf of investors who purchased shares between February 26, 2025, and February 24, 2026, highlighting significant investor concerns regarding the company's transparency.
- Financial Performance Warning: Oddity Tech disclosed on February 25, 2026, that it expects a 30% year-over-year decline in first-quarter 2026 revenue, primarily due to rising customer acquisition costs, indicating severe financial challenges ahead for the company.
- Stock Price Plummet: Following the lawsuit announcement, Oddity Tech's Class A ordinary shares fell by $14.28, or 49.21%, closing at $14.74, reflecting market pessimism about the company's future prospects.
- Algorithm Risk Disclosure: The lawsuit alleges that Oddity Tech failed to disclose risks associated with algorithm changes from its largest advertising partner, which diverted ads to lower-quality auctions at abnormally high costs, exacerbating investor concerns about the sustainability of its operating model.
See More
ODDITY Tech Faces Securities Class Action Lawsuit
- Stock Price Plunge: ODDITY Tech's shares plummeted 49% on February 25, 2026, resulting in a market cap loss exceeding $600 million, reflecting severe investor concerns about the company's financial outlook, particularly after announcing a projected 30% year-over-year decline in Q1 2026 revenue.
- Lawsuit Context: A securities class action lawsuit has been filed against ODDITY, representing investors who purchased its securities between February 26, 2025, and February 24, 2026, alleging the company made false and misleading statements while failing to disclose critical algorithm changes that led to significant investor losses.
- Advertising Partnership Issues: The lawsuit highlights that changes in the algorithm of ODDITY's largest advertising partner diverted ads to lower-quality auctions, significantly increasing customer acquisition costs, which not only impacted the company's business performance but also eroded financial prospects, exacerbating market distrust.
- Investor Rights Protection: Hagens Berman is investigating whether ODDITY intentionally misled investors and is encouraging affected investors to submit claims, demonstrating a commitment to investor rights and a strong demand for corporate transparency.
See More
Reminder for Oddity Tech Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Oddity Tech (NASDAQ: ODD) securities between February 26, 2025, and February 24, 2026, that they must apply to be lead plaintiff by May 11, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Oddity class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Oddity made false and misleading statements during the class period, resulting in investors suffering losses due to abnormally high advertising costs, which negatively impacted the company's financial outlook and market position.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Oddity Tech Faces Securities Litigation Investigation
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Oddity Tech Ltd., reminding investors of the May 11, 2026 deadline to seek lead plaintiff status in a federal securities class action filed against the company.
- Investor Loss Focus: Securities litigation partner James (Josh) Wilson encourages investors who purchased or acquired Oddity securities between February 26, 2025, and February 24, 2026, to contact him directly to discuss their legal rights and possible remedies.
- Contact Information Provided: Investors can reach Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) for more information and to understand their legal options regarding the ongoing investigation.
- Significance of Class Action: This investigation and the forthcoming lawsuit could negatively impact Oddity's stock price and corporate reputation, prompting investors to closely monitor developments to safeguard their interests.
See More
Reminder of Class Action for ODDITY Tech Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased ODDITY Tech Ltd. (NASDAQ: ODD) common stock between February 26, 2025, and February 24, 2026, that they must apply to be lead plaintiff by May 11, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to seek legal recourse without financial burden.
- Lawsuit Background: The lawsuit alleges that defendants misled investors by providing overly optimistic information about ODDITY Tech's 2027 financial targets while concealing the true state of its salesforce, resulting in investor losses once the actual details became public.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved significant settlements, including the largest securities class action against a Chinese company, demonstrating its extensive experience and success in handling such cases.
See More
Oddity Tech Faces Class Action Lawsuit Impacting Stock Price
- Class Action Initiated: Berger Montague PC has announced a class action lawsuit against Oddity Tech on behalf of investors who purchased shares between February 26, 2025, and February 24, 2026, highlighting significant investor concerns regarding the company's transparency.
- Financial Performance Warning: Oddity Tech disclosed on February 25, 2026, that it expects a 30% year-over-year decline in first-quarter 2026 revenue, primarily due to rising customer acquisition costs, indicating severe financial challenges ahead for the company.
- Stock Price Plummet: Following the lawsuit announcement, Oddity Tech's Class A ordinary shares fell by $14.28, or 49.21%, closing at $14.74, reflecting market pessimism about the company's future prospects.
- Algorithm Risk Disclosure: The lawsuit alleges that Oddity Tech failed to disclose risks associated with algorithm changes from its largest advertising partner, which diverted ads to lower-quality auctions at abnormally high costs, exacerbating investor concerns about the sustainability of its operating model.
See More
ODDITY Tech Faces Securities Class Action Lawsuit
- Stock Price Plunge: ODDITY Tech's shares plummeted 49% on February 25, 2026, resulting in a market cap loss exceeding $600 million, reflecting severe investor concerns about the company's financial outlook, particularly after announcing a projected 30% year-over-year decline in Q1 2026 revenue.
- Lawsuit Context: A securities class action lawsuit has been filed against ODDITY, representing investors who purchased its securities between February 26, 2025, and February 24, 2026, alleging the company made false and misleading statements while failing to disclose critical algorithm changes that led to significant investor losses.
- Advertising Partnership Issues: The lawsuit highlights that changes in the algorithm of ODDITY's largest advertising partner diverted ads to lower-quality auctions, significantly increasing customer acquisition costs, which not only impacted the company's business performance but also eroded financial prospects, exacerbating market distrust.
- Investor Rights Protection: Hagens Berman is investigating whether ODDITY intentionally misled investors and is encouraging affected investors to submit claims, demonstrating a commitment to investor rights and a strong demand for corporate transparency.
See More
Reminder for Oddity Tech Shareholder Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Oddity Tech (NASDAQ: ODD) securities between February 26, 2025, and February 24, 2026, that they must apply to be lead plaintiff by May 11, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the Oddity class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, minimizing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Oddity made false and misleading statements during the class period, resulting in investors suffering losses due to abnormally high advertising costs, which negatively impacted the company's financial outlook and market position.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and successful track record in this field.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
